Powerful Alliance to Fight Cancer
On May 28, 2026, Pfizer Inc. and Innovent Biologics announced a global strategic licensing and collaboration agreement to co-develop 12 breakthrough early-stage and new cancer medicines. The portfolio includes antibody-drug conjugates (ADCs) with novel differentiated payloads and multispecific antibodies with unique immune-engaging features.
Key Highlights
- 12 programs: 8 originated from Innovent, 4 proposed by Pfizer.
- Clear division of work: Innovent leads early development through Phase 1, while Pfizer oversees subsequent global development.
- Shared costs and profits: Certain programs will be co-developed and co-commercialized, with profit sharing.
Financial Terms
Innovent will receive a $650 million upfront payment and is eligible for up to $9.85 billion in milestone payments. Additionally, Innovent will receive up to double-digit royalties on sales of each approved product.
Hope for Patients
Jeff Legos, Chief Oncology Officer at Pfizer, stated: 'This collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting.' Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) at Innovent, added: 'By leveraging both companies' complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide.'
About Pfizer Oncology
Pfizer Oncology focuses on small molecules, antibody-drug conjugates (ADCs), and multispecific immune-engaging antibodies to fight common cancers including breast, gastrointestinal, genitourinary, hematologic malignancies, and lung cancer.
About Innovent Biologics
Innovent is a leading biopharmaceutical company dedicated to developing high-quality innovative drugs for serious diseases, including cancer.